Tuoxin Pharmaceutical Group Co.,Ltd. (SHE:301089)
30.71
-1.93 (-5.91%)
At close: Jan 29, 2026
SHE:301089 Balance Sheet
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 | Dec '20 Dec 31, 2020 |
Cash & Equivalents | 69.56 | 69.23 | 148.55 | 307.09 | 284.22 | 158.22 |
Trading Asset Securities | 185.28 | 250.88 | 190.7 | 240.16 | 220.62 | - |
Cash & Short-Term Investments | 254.83 | 320.11 | 339.26 | 547.25 | 504.84 | 158.22 |
Cash Growth | -28.75% | -5.64% | -38.01% | 8.40% | 219.08% | 52.49% |
Accounts Receivable | 132.45 | 151.52 | 235.3 | 205.41 | 103.58 | 92.11 |
Other Receivables | 0.2 | 21.32 | 12.57 | 13.66 | 0.62 | 0.28 |
Receivables | 132.65 | 172.84 | 247.87 | 219.07 | 104.2 | 92.39 |
Inventory | 190.79 | 178.88 | 204.11 | 241.14 | 167.08 | 159.9 |
Other Current Assets | 30.12 | 5.18 | 30.93 | 6.54 | 20.64 | 4.41 |
Total Current Assets | 608.39 | 677.01 | 822.17 | 1,014 | 796.76 | 414.91 |
Property, Plant & Equipment | 860.66 | 874.54 | 809.38 | 610.26 | 449.11 | 415.14 |
Long-Term Investments | 17.95 | 7.95 | 8.37 | 10.86 | 12.54 | 15.62 |
Other Intangible Assets | 79.73 | 81.83 | 84.04 | 84.26 | 84.56 | 71.02 |
Long-Term Accounts Receivable | 0.27 | 0.26 | - | - | - | - |
Long-Term Deferred Tax Assets | 75.47 | 69.58 | 63.71 | 70.36 | 6.51 | 7.66 |
Long-Term Deferred Charges | 2.87 | 4 | 2.7 | 1.86 | 2.33 | 8.01 |
Other Long-Term Assets | 44.02 | 43.08 | 48.62 | 51.64 | 41.9 | 14.11 |
Total Assets | 1,689 | 1,758 | 1,839 | 1,843 | 1,394 | 946.48 |
Accounts Payable | 103.41 | 133.21 | 152.55 | 158.58 | 162.94 | 213.38 |
Accrued Expenses | 8.29 | 22.81 | 24.58 | 69.09 | 17.51 | 21.08 |
Short-Term Debt | - | - | - | 40.03 | 64.5 | 147.41 |
Current Portion of Leases | 0.88 | 0.97 | - | - | 4.91 | 18.44 |
Current Income Taxes Payable | 2 | - | 0 | 66.05 | 1.31 | 2.37 |
Current Unearned Revenue | 2.97 | 0.91 | 5.48 | 71.89 | 2.9 | 15.66 |
Other Current Liabilities | 12.3 | 7.43 | 11.9 | 18.32 | 0.53 | 2.15 |
Total Current Liabilities | 129.84 | 165.32 | 194.51 | 423.96 | 254.6 | 420.5 |
Long-Term Debt | - | - | - | - | - | 4.8 |
Long-Term Leases | 2.34 | 3.25 | - | - | - | 4.91 |
Long-Term Unearned Revenue | 31.4 | 32.94 | 35.17 | 38.31 | 40.4 | 23.57 |
Long-Term Deferred Tax Liabilities | 3.42 | 4.21 | 6.04 | 4.61 | 1.36 | 1.83 |
Total Liabilities | 167.01 | 205.72 | 235.72 | 466.89 | 296.35 | 455.61 |
Common Stock | 126.54 | 126.54 | 126.54 | 126 | 126 | 94.5 |
Additional Paid-In Capital | 621.11 | 621.11 | 621.11 | 585.3 | 578.54 | 66.77 |
Retained Earnings | 772.49 | 802.66 | 854.18 | 661.5 | 387.57 | 321.86 |
Comprehensive Income & Other | 2.21 | 2.21 | 1.44 | 3.57 | 5.25 | 7.75 |
Total Common Equity | 1,522 | 1,553 | 1,603 | 1,376 | 1,097 | 490.87 |
Shareholders' Equity | 1,522 | 1,553 | 1,603 | 1,376 | 1,097 | 490.87 |
Total Liabilities & Equity | 1,689 | 1,758 | 1,839 | 1,843 | 1,394 | 946.48 |
Total Debt | 3.22 | 4.22 | - | 40.03 | 69.41 | 175.56 |
Net Cash (Debt) | 251.61 | 315.89 | 339.26 | 507.22 | 435.43 | -17.34 |
Net Cash Growth | -29.65% | -6.89% | -33.11% | 16.49% | - | - |
Net Cash Per Share | 2.11 | 2.54 | 2.69 | 4.02 | 4.37 | -0.18 |
Filing Date Shares Outstanding | 126.54 | 126.54 | 126.54 | 126 | 126 | 94.5 |
Total Common Shares Outstanding | 126.54 | 126.54 | 126.54 | 126 | 126 | 94.5 |
Working Capital | 478.55 | 511.69 | 627.66 | 590.04 | 542.16 | -5.59 |
Book Value Per Share | 12.03 | 12.27 | 12.67 | 10.92 | 8.71 | 5.19 |
Tangible Book Value | 1,443 | 1,471 | 1,519 | 1,292 | 1,013 | 419.85 |
Tangible Book Value Per Share | 11.40 | 11.62 | 12.01 | 10.25 | 8.04 | 4.44 |
Buildings | - | 283.94 | 267.66 | 257.26 | 210.62 | 101.8 |
Machinery | - | 420.02 | 382.3 | 354.84 | 301.65 | 195.05 |
Construction In Progress | - | 372.68 | 331.03 | 130.48 | 35.59 | 266.05 |
Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.